About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New Study Suggests Heparin is a Cheaper Option in Treating Common Heart Attacks

by Kathy Jones on July 5, 2014 at 11:56 PM
Font : A-A+

 New Study Suggests Heparin is a Cheaper Option in Treating Common Heart Attacks

Results of a new study that compared the effectiveness of two drugs in treating heart attacks has found that one of the drugs, heparin, led to improved outcomes, including reducing the rate of repeat heart attacks, compared to bivalirudin which is a popular drug in high income countries and is 400 times more expensive than heparin. The study appears in The Lancet.

The results of the HEAT-PPCI trial suggest that systematic use of heparin rather than bivalirudin after primary percutaneous coronary intervention (PPCI) - the most commonly used treatment for heart attack, which unblocks the arteries carrying blood to the heart - could save health services substantial sums of money, at the same time as potentially improving patient outcomes. Patients who undergo PPCI usually receive a combination of antithrombotic drugs to prevent any further blood clots forming during the procedure and after it has been completed.

Advertisement

The most commonly used antithrombotic drugs are unfractionated heparin and bivalirudin, and although several previous trials have compared the two drugs, the evidence is unclear as to which drug results in better outcomes. The trial took place at the Liverpool Heart and Chest Hospital in the UK, where 1829 patients undergoing emergency angiography (an x-ray examination of the heart's arteries after a suspected heart attack) were recruited to the trial. More than four fifths of these patients then went on to receive PPCI; approximately half received heparin, and half received bivalirudin.

Researchers then recorded how many patients in both groups experienced a major adverse cardiac event, such as death or another heart attack, within 28 days after surgery. The results show that overall rates of major adverse cardiac events were significantly lower in the group who received heparin, although the rates of adverse events were low, as expected, in both groups. Within 28 days after surgery, 46 patients (5•1%) in the bivalirudin group died, compared to 39 (4•3%) of patients in the heparin group; 24 patients (2•7%) in the bivalirudin group had another heart attack in the same period, compared to 7 patients (0•8%) in the heparin group. Although bleeding complications are an acknowledged risk of antithrombotic drugs, there was no significant difference between the groups in the rate of complications.
Advertisement

According to lead author Dr Rod Stables, of the Liverpool Heart and Chest Hospital NHS Foundation Trust, UK, "As far as we are aware, our study is one of the first trials to recruit 100% of eligible patients presenting with the medical condition being examined, which means that it more closely resembles real life practice than many previous trials. The results suggest that the use of heparin has some advantage over bivalirudin in avoiding major adverse events, mainly in terms of reduced recurrent, additional heart attacks in patients recovering from PPCI. This finding might provide an opportunity, rare in modern health care, to provide improved outcomes at much reduced cost." In a linked Comment, Peter Berger and James Blankenship of Geisinger Health System, in Pennsylvania, USA, point out that the although the study has a number of limitations - including an open-label, single-centre design - the study has the advantage of closely resembling actual clinical practice, and including many patients who would have been excluded from earlier trials comparing the two drugs.

They write that, "Even if heparin alone had produced statistically similar outcomes to bivalirudin, it would have been a win for heparin. A drug that costs less than a 1/400th of another that has similar efficacy and safety ought to be used preferentially." The design of the HEAT-PPCI trial has attracted some criticism within the medical community because of its use of delayed consent: patients provided their consent to participate only after they had been given either heparin or bivalirudin, leading some doctors to raise concerns that the trial design did not conform to medical ethics standards. However, in a second linked Comment, David Shaw, of the Institute for Biomedical Ethics in Basel, Switzerland, disputes these criticisms, writing that, "In this context, the strategy was preferable to attempting to obtain consent from potentially incompetent patients needing extremely urgent cardiac treatment... In routine clinical care, it would be perfectly normal for a doctor to choose either heparin or bivalirudin without involvement of the patient in the decision." "Informed consent for percutaneous coronary intervention is frequently not sought at all; why patients should be asked to consent in advance to formal randomisation of a drug used in the intervention is thus unclear. It would have been unethical to have done the study differently. Attempting to get consent from patients would have increased the risk of harming them by delaying treatment, and could also have affected recruitment."



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Printed Temperature Sensors help with Continuous Temperature Monitoring
Health Benefits of Giloy
Breast Cancer Awareness Month 2021 - It's time to RISE
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Heart Healthy Heart Amyotrophic Lateral Sclerosis (ALS) Statins Mitral Valve Prolapse Aortic Valve Stenosis Anticoagulants Pulmonary Embolism Pericarditis 

Recommended Reading
Heart Attack- Lifestyle risks
Heart attack is the death of the heart muscle due to loss of blood supply. Simple guidelines to ......
Heart Attack
Heart attack is the death of the heart muscle due to loss of blood supply. Heart disease is the ......
Lifestyle Paths to Heart Disease
Heart disease can be of many types depending upon whether they involve the heart muscles or artery ...
Amyotrophic Lateral Sclerosis (ALS)
Find out more about the degenerative disease- Amyotrophic lateral sclerosis....
Anticoagulants
Anticoagulants prevent the clotting of blood in our body. They are administered orally or via ......
Aortic Valve Stenosis
Aortic valve Stenosis is an abnormal narrowing of the c valve. Symptoms include angina, and that of ...
Mitral Valve Prolapse
Mitral Valve Prolapse is a relatively common condition and causes leakage of blood through the valve...
Pericarditis
Pericarditis occurs when the pericardium gets inflamed. Pericarditis is characterized by severe ches...
Pulmonary Embolism
Pulmonary embolism (PE) is a complication that results from a block in the main artery supplying the...
Statins
Statins are new wonder drugs that are proving to be efficacious, not merely in relieving symptoms bu...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use